Valneva receives positive chmp opinion for marketing authorization of its inactivated covid-19 vaccine candidate in europe

Saint herblain (france ), june 23 , 2022 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has recommended marketing authorization in europe for valneva's inactivated whole-virus covid-19 vaccine candidate, vla2001, for use as primary vaccination in people from 18 to 50 years of age.
VALN Ratings Summary
VALN Quant Ranking